Condition
Clinically Significant Prostate Cancer
Total Trials
5
Recruiting
4
Active
4
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 25/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.4% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
100%
1 of 1 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
2Total
Not Applicable (2)
Trial Status
Recruiting4
Completed1
Trial Success Rate
100.0%
Benchmark: 86.6%
Based on 1 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT07710807Not ApplicableRecruiting
Transperineal Versus Transrectal Cognitive Fusion Prostate Biopsy
NCT07614256Recruiting
Multimodal Imaging and Digital Pathology for Prostate Cancer Prediction
NCT07492927RecruitingPrimary
Plasma exoRNA-Based Liquid Biopsy to Diagnose Clinically Significant Prostate Cancer
NCT07168616Recruiting
Study of PSMA PET/CT Imaging to Help Select Men With Low-Risk Prostate Cancer for Active Surveillance
NCT03044197Not ApplicableCompleted
Detection of Clinically Significant Prostate Cancer Using Transperineal Targeted Biopsy Compared to Standard Transrectal Biopsy
Showing all 5 trials